Deals Of The Week: Hunting For Dengue Fever Drugs Amid Climate Change
Executive Summary
Plus news of deals between Sanofi and Pozen, Otsuka and Astex, Santhera and Takeda, Ultragenyx and Kyowa, Baxter and Coherus Biosciences, Novartis and Regenerex, and more.
You may also be interested in...
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.
Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?
Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.